查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1586115

心臟生物标记市场：按类型、测试地点、应用划分 - 2025-2030 年全球预测

Cardiac Biomarker Market by Type (Brain Natriuretic Peptide or NT-proBNP, Creatine Kinase, Ischemia Modified Albumin), Location of Testing (Laboratory Testing, Point of Care Testing), Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

心臟生物标记市场2023年估值为46.2亿美元，预计到2024年将达到53.1亿美元，复合年增长率为14.90%，到2030年将达到122.4亿美元。

心臟生物标记是用于检测和评估急性冠状动脉症候群和心臟衰竭等心臟疾病的重要诊断工具。这些生物标记是心臟受损时释放到血液中的蛋白质和酶，可帮助了解病情的严重程度。对心臟生物标记的需求在于其非侵入性，提供快速可靠的诊断讯息，这对于心臟相关疾病的早期疗育和管理至关重要。心臟生物标记广泛应用于临床实践，以指南诊断、风险分层和治疗计划。典型的最终用户包括医院、诊断实验室和活跃于心血管研究的研究机构。

主要市场统计
基准年[2023] 46.2亿美元
预测年份 [2024] 53.1亿美元
预测年份 [2030] 122.4亿美元
复合年增长率（%） 14.90%

由于心血管疾病盛行率上升、对就地检验的需求不断增加以及生物标记发现和检验的进步等因素，心臟生物标记市场的成长得到了推动。新的商机包括开发可提高敏感性和特异性的新型生物标记物，以及促进远端监测和及时干预的数位健康解决方案的普及。对公司的主要建议是专注于协作研发，以创新并提供涵盖传统和新型生物标记的综合测试解决方案。

然而，市场面临一些限制，例如与生物标记发现相关的高成本以及延长产品开发时间的严格监管要求。此外，患者群体中生物标记值的变异性可能会对基于生物标记的检测的临床效用和商业化提出挑战。

在整合人工智慧和机器学习以增强生物标记分析和解释，以及开发多重检测以提供全面的心臟诊断方面，创新机会比比皆是。专注于生物标记产生的遗传基础的研究可以透过根据个人的遗传特征定制诊断工具来实现精准医疗，并推动未来的市场成长。市场竞争仍在继续，全面的心臟健康监测系统的努力为全面的疾病管理解决方案提供了一条有希望的道路。

市场动态：揭示快速发展的心臟生物标记市场的关键市场洞察

供需的动态交互作用正在改变心臟生物标记市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球心血管疾病盛行率不断上升
    • 提高对心血管疾病早期诊断的认识和需求
    • 与人口老化相关的心臟病迅速增加
  • 市场限制因素
    • 与样本采集和储存相关的技术问题
  • 市场机会
    • 增加心臟生物标记研发活动的投资
    • 使用心臟生物标记进行 POC 测试的需求不断增加
  • 市场挑战
    • 对监管和报销制度的担忧

波特的五力：驾驭心臟生物标记市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解心臟生物标记市场的外部影响

外部宏观环境因素在塑造心臟生物标记市场的表现动态方面发挥关键作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解心臟生物标记市场的竞争格局

心臟生物标记市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，以应对日益激烈的竞争。

FPNV 定位矩阵心臟生物标记市场供应商的绩效评估

FPNV定位矩阵是评估心臟生物标记市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议绘製心臟生物标记市场的成功之路

心臟生物标记市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球心血管疾病发生率增加
      • 提高对心血管疾病早期诊断的认识和需求
      • 心臟病与老年人口的快速成长有关
    • 抑制因素
      • 样本采集与储存的技术问题
    • 机会
      • 对心臟生物标记研发活动的新投资
      • 使用心臟生物标记进行 POC 测试的需求不断增加
    • 任务
      • 监管和报销问题
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章心臟生物标记市场：按类型

  • 脑钠胜肽或 NT-proBNP
  • 肌酸激酶
  • 缺血修饰白蛋白
  • 肌红蛋白
  • 肌钙蛋白

第七章按测试地点分類的心臟生物标记市场

  • 临床检查
  • 就地检验

第八章心臟生物标记市场：依应用分类

  • 急性冠状动脉症候群
  • 动脉硬化
  • 郁血性心臟衰竭
  • 心肌梗塞

第九章美洲心臟生物标记市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区心臟生物标记市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲的心臟生物标记市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • bioMerieux SA
  • DiaSorin SpA
  • F. Hoffmann-La Roche Ltd.
  • Guangzhou Wondfo Biotech Co., Ltd.
  • Johnson & Johnson Services, Inc.
  • Olympus Corporation
  • PerkinElmer Inc.
  • Quidel Corporation
  • Randox Laboratories Ltd.
  • Siemens Healthcare GmbH
  • Thermo Fisher Scientific Inc.
  • Tosoh Corporation
Product Code: MRR-433AB1DC288D

The Cardiac Biomarker Market was valued at USD 4.62 billion in 2023, expected to reach USD 5.31 billion in 2024, and is projected to grow at a CAGR of 14.90%, to USD 12.24 billion by 2030.

Cardiac biomarkers are crucial diagnostic tools used for the detection and evaluation of heart conditions, including acute coronary syndrome and heart failure. These biomarkers are proteins or enzymes released into the blood when the heart is damaged, offering insights into the condition's severity. The necessity for cardiac biomarkers lies in their non-invasive nature, providing quick and reliable diagnostic information pivotal for early intervention and management of heart-related diseases. They are widely used in clinical settings for diagnosis, risk stratification, and as a measure to guide treatment plans. Major end-users include hospitals, diagnostic laboratories, and research institutions actively involved in cardiovascular studies.

KEY MARKET STATISTICS
Base Year [2023] USD 4.62 billion
Estimated Year [2024] USD 5.31 billion
Forecast Year [2030] USD 12.24 billion
CAGR (%) 14.90%

The cardiac biomarker market is primed for growth due to factors such as the rising prevalence of cardiovascular diseases, increasing demand for point-of-care testing, and advancements in biomarker discovery and validation. Emerging opportunities include the development of novel biomarkers that offer enhanced sensitivity and specificity, coupled with the proliferation of digital health solutions that facilitate remote monitoring and timely intervention. A key recommendation for businesses is to focus on collaborative research and development to innovate and provide integrated testing solutions that encompass both traditional and novel biomarkers.

However, the market faces limitations like high costs associated with biomarker discovery and stringent regulatory requirements that lengthen product development timelines. Additionally, the variability in biomarker levels among different patient populations can challenge the clinical utility and commercialization of biomarker-based assays.

Innovation opportunities are abundant in the integration of artificial intelligence and machine learning to enhance biomarker analysis and interpretation, as well as in developing multiplex assays that provide comprehensive cardiac diagnostics. Research focusing on the genetic basis of biomarker production, implementing precision medicine by tailoring diagnostic tools to individual genetic profiles, can drive future market growth. The market remains competitive, with a push towards holistic cardiac health monitoring systems, offering a promising avenue for comprehensive disease management solutions.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cardiac Biomarker Market

The Cardiac Biomarker Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing incidence of cardiovascular diseases globally
    • Increasing awareness and need for early diagnosis of cardiovascular diseases
    • Surge in geriatric population and related heart diseases
  • Market Restraints
    • Technical issues pertinent to sample collection and storage
  • Market Opportunities
    • Emerging investment in research and development activities in cardiac biomarkers
    • Emerging demand for POC testing with cardiac biomarkers
  • Market Challenges
    • Concerns over regulatory and reimbursement systems

Porter's Five Forces: A Strategic Tool for Navigating the Cardiac Biomarker Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cardiac Biomarker Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cardiac Biomarker Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cardiac Biomarker Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cardiac Biomarker Market

A detailed market share analysis in the Cardiac Biomarker Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cardiac Biomarker Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cardiac Biomarker Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cardiac Biomarker Market

A strategic analysis of the Cardiac Biomarker Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cardiac Biomarker Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Beckman Coulter, Inc., Becton, Dickinson and Company, bioMerieux SA, DiaSorin S.p.A., F. Hoffmann-La Roche Ltd., Guangzhou Wondfo Biotech Co., Ltd., Johnson & Johnson Services, Inc., Olympus Corporation, PerkinElmer Inc., Quidel Corporation, Randox Laboratories Ltd., Siemens Healthcare GmbH, Thermo Fisher Scientific Inc., and Tosoh Corporation.

Market Segmentation & Coverage

This research report categorizes the Cardiac Biomarker Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Brain Natriuretic Peptide or NT-proBNP, Creatine Kinase, Ischemia Modified Albumin, Myoglobin, and Troponins.
  • Based on Location of Testing, market is studied across Laboratory Testing and Point of Care Testing.
  • Based on Application, market is studied across Acute Coronary Syndrome, Atherosclerosis, Congestive Heart Failure, and Myocardial Infarction.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing incidence of cardiovascular diseases globally
      • 5.1.1.2. Increasing awareness and need for early diagnosis of cardiovascular diseases
      • 5.1.1.3. Surge in geriatric population and related heart diseases
    • 5.1.2. Restraints
      • 5.1.2.1. Technical issues pertinent to sample collection and storage
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging investment in research and development activities in cardiac biomarkers
      • 5.1.3.2. Emerging demand for POC testing with cardiac biomarkers
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns over regulatory and reimbursement systems
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cardiac Biomarker Market, by Type

  • 6.1. Introduction
  • 6.2. Brain Natriuretic Peptide or NT-proBNP
  • 6.3. Creatine Kinase
  • 6.4. Ischemia Modified Albumin
  • 6.5. Myoglobin
  • 6.6. Troponins

7. Cardiac Biomarker Market, by Location of Testing

  • 7.1. Introduction
  • 7.2. Laboratory Testing
  • 7.3. Point of Care Testing

8. Cardiac Biomarker Market, by Application

  • 8.1. Introduction
  • 8.2. Acute Coronary Syndrome
  • 8.3. Atherosclerosis
  • 8.4. Congestive Heart Failure
  • 8.5. Myocardial Infarction

9. Americas Cardiac Biomarker Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Cardiac Biomarker Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Cardiac Biomarker Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Beckman Coulter, Inc.
  • 3. Becton, Dickinson and Company
  • 4. bioMerieux SA
  • 5. DiaSorin S.p.A.
  • 6. F. Hoffmann-La Roche Ltd.
  • 7. Guangzhou Wondfo Biotech Co., Ltd.
  • 8. Johnson & Johnson Services, Inc.
  • 9. Olympus Corporation
  • 10. PerkinElmer Inc.
  • 11. Quidel Corporation
  • 12. Randox Laboratories Ltd.
  • 13. Siemens Healthcare GmbH
  • 14. Thermo Fisher Scientific Inc.
  • 15. Tosoh Corporation

LIST OF FIGURES

  • FIGURE 1. CARDIAC BIOMARKER MARKET RESEARCH PROCESS
  • FIGURE 2. CARDIAC BIOMARKER MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CARDIAC BIOMARKER MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. CARDIAC BIOMARKER MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. CARDIAC BIOMARKER MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CARDIAC BIOMARKER MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CARDIAC BIOMARKER MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CARDIAC BIOMARKER MARKET DYNAMICS
  • TABLE 7. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY BRAIN NATRIURETIC PEPTIDE OR NT-PROBNP, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY CREATINE KINASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY ISCHEMIA MODIFIED ALBUMIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY MYOGLOBIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY TROPONINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY POINT OF CARE TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY ATHEROSCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM CARDIAC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM CARDIAC BIOMARKER MARKET SIZE, BY LOCATION OF TESTING, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. CARDIAC BIOMARKER MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. CARDIAC BIOMARKER MARKET, FPNV POSITIONING MATRIX, 2023